Literature DB >> 3079598

Adrenal abnormalities in polycystic ovary syndrome.

T Loughlin, S Cunningham, A Moore, M Culliton, P P Smyth, T J McKenna.   

Abstract

This study was undertaken to examine the role of adrenal androgen excess in the pathogenesis of polycystic ovary syndrome (PCOS) and, if such was present, to assess its reversibility using dexamethasone given in physiological dosage at night. Mean plasma testosterone (T), T/sex-hormone binding globulin (T/SHBG) ratio, androstenedione, and 17-OH-progesterone levels were elevated in the 19 patients studied. Plasma estrone values were elevated, whereas estradiol levels were normal. Plasma FSH was decreased and LH responsiveness to LHRH was exaggerated. Metyrapone, an 11-hydroxylase inhibitor, was administered at 2400 h to induce hypocortisolemia and compensatory ACTH secretion so that adrenal androgen and glucocorticoid responsiveness to endogenous stimulation could be examined. Plasma T, androstenedione, and 11-deoxycortisol responses to metyrapone were excessive in PCOS patients, thus indicating a specific adrenal abnormality. After 3 months treatment with dexamethasone, 0.5 mg at night, mean plasma T/SHBG and androstenedione declined to normal, and mean plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate declined to below normal. The mean estrone value was slightly lower during dexamethasone. Plasma LH responsiveness to LHRH was no longer significantly different from normal, but FSH was suppressed. During treatment androgen responsiveness to metyrapone stimulation was normal, whereas 11-deoxycortisol responsiveness was suppressed. Fifteen patients completed 3 months of treatment with dexamethasone. Of these, 10 resumed regular menstruation. The latter group had suppression of plasma T, T/SHBG, androstenedione, dehydroepiandrosterone, and dehydroepiandrosterone sulfate. Only plasma androstenedione fell significantly in the remainder. These observations support the hypothesis that, in at least some patients, PCOS develops in response to abnormal gonadotropin secretion induced by hyperestronemia occurring as a consequence of excessive adrenal androgen secretion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079598     DOI: 10.1210/jcem-62-1-142

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan
Journal:  Psychopharmacology (Berl)       Date:  2014-06-21       Impact factor: 4.530

2.  Androgen-producing bilateral large cortical adrenal adenomas associated with polycystic ovaries in a young female.

Authors:  D Micić; S Zorić; V Popović; R Janković; M Jancić; R Han; D Manojlović; J Mićić
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

3.  Value of buserelin testing in the evaluation of hirsute women.

Authors:  B Ambrosi; T Re; E Passini; D Bochicchio; R Ferrario
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

4.  Plasma pro-opiomelanocortin fragments and adrenal steroids following administration of metyrapone to normal and hirsute women.

Authors:  S K Cunningham; T Loughlin; X Bertagna; F Girard; T J McKenna
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

5.  Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome.

Authors:  A Mongioì; M Macchi; E Vicari; M C Fornito; A E Calogero; C Riccioli; G Minacapilli; M L Moncada; R D'Agata
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

6.  Transcutaneous electrical acupoint stimulation alleviates the hyperandrogenism of polycystic ovarian syndrome rats by regulating the expression of P450arom and CTGF in the ovaries.

Authors:  Fan Qu; Yi Liang; Jue Zhou; Rui-Jie Ma; Jie Zhou; Fang-Fang Wang; Yan Wu; Jian-Qiao Fang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

7.  A role for a non-androgenic anovulant in the management of hirsutism.

Authors:  T J McKenna; S K Cunningham
Journal:  Ir J Med Sci       Date:  1991-07       Impact factor: 1.568

8.  Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome.

Authors:  Evgenia Gourgari; Maya Lodish; Meg Keil; Ninet Sinaii; Evrim Turkbey; Charalampos Lyssikatos; Maria Nesterova; Maria de la Luz Sierra; Paraskevi Xekouki; Divya Khurana; Svetlana Ten; Adrian Dobs; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2016-06-23       Impact factor: 5.958

9.  The changing role of the clinical laboratory in the investigation of polycystic ovarian syndrome.

Authors:  A Michael Wallace; Naveed Sattar
Journal:  Clin Biochem Rev       Date:  2007-08

10.  Roux-en-Y gastric bypass in the treatment of non-classic congenital adrenal hyperplasia due to 11-hydroxylase deficiency.

Authors:  Amir Kalani; Nithin Thomas; Alan Sacerdote; Gül Bahtiyar
Journal:  BMJ Case Rep       Date:  2013-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.